Phase II trial of Cetuximab in the Treatment of Persistent or Recurrent Squamous or Non-Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study

PURPOSE: The Gynecologic Oncology Group (GOG) conducted a phase II trial to assess the efficacy and tolerability of the anti-EGFR antibody cetuximab, in persistent or recurrent carcinoma of the cervix. PATIENTS AND METHODS: Eligible patients had cervical cancer, measurable disease, and GOG performan...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Santin, Alessandro D., Sill, Michael W., McMeekin, D. Scott, Leitao, Mario M., Brown, Jubilee, Sutton, Gregory P., Van Le, Linda, Griffin, Patricia, Boardman, Cecelia H.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2011
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3152667/
https://ncbi.nlm.nih.gov/pubmed/21684583
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2011.05.040
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak